Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Ensysce Biosciences' Total Liabilities fell 1783.41% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 1783.41%. This contributed to the annual value of $2.2 million for FY2024, which is 3399.64% down from last year.
  • Ensysce Biosciences' Total Liabilities amounted to $2.3 million in Q3 2025, which was down 1783.41% from $2.5 million recorded in Q2 2025.
  • Ensysce Biosciences' 5-year Total Liabilities high stood at $24.6 million for Q4 2021, and its period low was $1.3 million during Q2 2024.
  • For the 5-year period, Ensysce Biosciences' Total Liabilities averaged around $6.6 million, with its median value being $3.7 million (2021).
  • As far as peak fluctuations go, Ensysce Biosciences' Total Liabilities skyrocketed by 25056.47% in 2021, and later plummeted by 8599.07% in 2023.
  • Ensysce Biosciences' Total Liabilities (Quarter) stood at $24.6 million in 2021, then crashed by 59.66% to $9.9 million in 2022, then plummeted by 66.12% to $3.4 million in 2023, then tumbled by 34.0% to $2.2 million in 2024, then increased by 3.94% to $2.3 million in 2025.
  • Its Total Liabilities was $2.3 million in Q3 2025, compared to $2.5 million in Q2 2025 and $1.9 million in Q1 2025.